• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估特应性皮炎女性在计划生育中认知的问卷的验证。

Validation of a Questionnaire to Assess the Perception of Women with Atopic Dermatitis in Family Planning.

机构信息

Dermatology Department, Hospital Universitario Virgen del Rocío, Avda. Manuel Siurot s/n, 41013 Sevilla, Spain.

Dermatology Department, Hospital Universitario San Cecilio, Avda. del Conocimiento s/n, 18016 Granda, Spain.

出版信息

Int J Environ Res Public Health. 2022 Aug 29;19(17):10753. doi: 10.3390/ijerph191710753.

DOI:10.3390/ijerph191710753
PMID:36078468
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9517831/
Abstract

INTRODUCTION

Atopic dermatitis (AD) is a highly frequent chronic inflammatory skin disease. It is important to know how women with AD approach family planning together with their disease. The aim of the present research is to develop and validate a questionnaire for women diagnosed with AD in order to measure their level of desire and gestational information.

MATERIALS AND METHODS

A multicenter cross-sectional study was conducted. Women between 18 and 45 years old with mild, moderate, and severe forms of the disease were included and disease-free controls. An exploratory factorial analysis of the primary components and varimax rotation was used to measure the validity of the construct. Cronbach's α was used to measure the reliability of the individual scales and the global questionnaire.

RESULTS

In total, 150 valid questionnaires were included. The final questionnaire consisted of 23 items that converged on six factors. The six scales had adequate reliability: "Pregnancy" (Cronbach's alpha = 0.95), "Conception" (Cronbach's alpha = 0.93), "Concern-information" (Cronbach's alpha = 0.82), "Breastfeeding" (Cronbach's alpha = 0.81), "Sexual life" (Cronbach's alpha = 0.79), and "Family planning" (Cronbach's alpha = 0.67). The total Cronbach's alpha of the questionnaire was 0.94.

DISCUSSION

This questionnaire is the first specific measurement instrument developed for women with AD of childbearing age that has demonstrated adequate levels of reliability and construct validity. We consider it useful and valuable to study aspects such as family planning in this patient profile, and that can influence their decision to have offspring.

摘要

简介

特应性皮炎(AD)是一种高发的慢性炎症性皮肤病。了解 AD 女性如何在疾病的同时规划家庭生育是很重要的。本研究旨在开发和验证用于评估 AD 女性生育愿望和妊娠信息的问卷,并对其进行验证。

材料与方法

本研究为多中心横断面研究,纳入 18-45 岁的轻、中、重度 AD 女性患者和无疾病对照。采用主成分分析和方差极大旋转进行探索性因子分析,以衡量结构的有效性。采用 Cronbach's α 评估个体量表和总体问卷的信度。

结果

共纳入 150 份有效问卷。最终问卷包含 23 个项目,汇聚为 6 个因子。6 个量表具有良好的信度:“妊娠”(Cronbach's α = 0.95)、“受孕”(Cronbach's α = 0.93)、“关注信息”(Cronbach's α = 0.82)、“母乳喂养”(Cronbach's α = 0.81)、“性生活”(Cronbach's α = 0.79)和“生育计划”(Cronbach's α = 0.67)。问卷的总 Cronbach's α 为 0.94。

讨论

本问卷是专为育龄期 AD 女性开发的首个特定测量工具,其信度和结构效度均令人满意。我们认为该问卷对于研究此类患者的生育计划等方面是有用且有价值的,这些方面可能会影响其生育决策。

相似文献

1
Validation of a Questionnaire to Assess the Perception of Women with Atopic Dermatitis in Family Planning.评估特应性皮炎女性在计划生育中认知的问卷的验证。
Int J Environ Res Public Health. 2022 Aug 29;19(17):10753. doi: 10.3390/ijerph191710753.
2
Development and validation of a questionnaire to measure empowerment in adult patients with atopic dermatitis. The DATEMP questionnaire.开发和验证一种用于评估特应性皮炎成年患者赋权感的问卷。DATEMP 问卷。
J Dtsch Dermatol Ges. 2019 Sep;17(9):923-931. doi: 10.1111/ddg.13934. Epub 2019 Sep 5.
3
Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT).评估特应性皮炎患者的自我控制感:特应性皮炎控制工具(ADCT)的设计、验证和评分。
Curr Med Res Opin. 2020 Mar;36(3):367-376. doi: 10.1080/03007995.2019.1699516. Epub 2019 Dec 12.
4
Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis.使用对接受生物制剂治疗的特应性皮炎患者的纵向调查验证特应性皮炎控制工具(ADCT©)
BMC Dermatol. 2019 Nov 6;19(1):15. doi: 10.1186/s12895-019-0095-3.
5
Atopic dermatitis burden scale: creation of a specific burden questionnaire for families.特应性皮炎负担量表:为家庭创建特定负担问卷。
J Eur Acad Dermatol Venereol. 2013 Nov;27(11):1426-32. doi: 10.1111/jdv.12180. Epub 2013 May 16.
6
Development and initial validation of a Traditional Chinese Medicine symptom-specific outcome measure: a Zheng-related atopic dermatitis symptom questionnaire (ZRADSQ).开发并初步验证一种针对中医症状的结局测量工具:与 Zheng 相关的特应性皮炎症状问卷(ZRADSQ)。
Health Qual Life Outcomes. 2013 Dec 21;11:212. doi: 10.1186/1477-7525-11-212.
7
[Self management in chronically ill adolescents: development of a short questionnaire].[慢性病青少年的自我管理:一份简短问卷的编制]
Rehabilitation (Stuttg). 2009 Aug;48(4):228-37. doi: 10.1055/s-0029-1234050. Epub 2009 Aug 17.
8
Atopic Dermatitis Burden Scale for Adults: Development and Validation of a New Assessment Tool.成人特应性皮炎负担量表:一种新评估工具的开发与验证
Acta Derm Venereol. 2015 Jul;95(6):700-5. doi: 10.2340/00015555-1945.
9
Development and validation of Chinese version of female sexual function index in a Chinese population-a pilot study.中文女性性功能指数在中国人群中的开发和验证-一项初步研究。
J Sex Med. 2011 Apr;8(4):1101-11. doi: 10.1111/j.1743-6109.2010.02171.x. Epub 2011 Jan 14.
10
Reliability and validity of the Arabic version of "dermatitis family impact" questionnaire in children with atopic dermatitis.特应性皮炎儿童“皮炎家庭影响”问卷阿拉伯文版的信度和效度。
Int J Dermatol. 2010 Sep;49(9):1063-7. doi: 10.1111/j.1365-4632.2010.04519.x.

引用本文的文献

1
Counselling Needs in Atopic Dermatitis: Perspectives on Pregnancy and Treatment.特应性皮炎的咨询需求:关于妊娠与治疗的观点
Acta Derm Venereol. 2025 Mar 7;105:adv42544. doi: 10.2340/actadv.v105.42544.
2
Impact of Atopic Dermatitis on Adult Women's Lives: A Survey of 1,009 French Women.特应性皮炎对成年女性生活的影响:对 1009 名法国女性的调查。
Acta Derm Venereol. 2024 May 13;104:adv10321. doi: 10.2340/actadv.v104.10321.

本文引用的文献

1
Sexual Dysfunction and Atopic Dermatitis: A Systematic Review.性功能障碍与特应性皮炎:一项系统综述。
Life (Basel). 2021 Nov 29;11(12):1314. doi: 10.3390/life11121314.
2
Sexual dysfunction in a cohort of patients with moderate-to-severe atopic dermatitis. Influence of dupilumab treatment.中重度特应性皮炎患者队列中的性功能障碍。度普利尤单抗治疗的影响。
Int J Dermatol. 2022 May;61(5):607-610. doi: 10.1111/ijd.15938. Epub 2021 Oct 11.
3
Immunosuppressive and Immunomodulating Therapy for Atopic Dermatitis in Pregnancy: An Appraisal of the Literature.孕期特应性皮炎的免疫抑制和免疫调节治疗:文献评估
Dermatol Ther (Heidelb). 2020 Dec;10(6):1215-1228. doi: 10.1007/s13555-020-00457-w. Epub 2020 Nov 2.
4
New emergent therapies for atopic dermatitis: A review of safety profile with respect to female fertility, pregnancy, and breastfeeding.特应性皮炎的新出现疗法:对女性生育力、妊娠和哺乳安全性的综述。
Dermatol Ther. 2021 Jan;34(1):e14475. doi: 10.1111/dth.14475. Epub 2020 Nov 5.
5
Pregnancy complications, treatment characteristics and birth outcomes in women with atopic dermatitis in Denmark.丹麦特应性皮炎女性的妊娠并发症、治疗特征和分娩结局。
J Eur Acad Dermatol Venereol. 2019 Mar;33(3):577-587. doi: 10.1111/jdv.15256. Epub 2018 Oct 8.
6
The Use and Safety of TNF Inhibitors during Pregnancy in Women with Psoriasis: A Review.TNF 抑制剂在银屑病女性妊娠期间的使用和安全性:综述。
Int J Mol Sci. 2018 May 3;19(5):1349. doi: 10.3390/ijms19051349.
7
Public Health Burden and Epidemiology of Atopic Dermatitis.特应性皮炎的公共卫生负担与流行病学
Dermatol Clin. 2017 Jul;35(3):283-289. doi: 10.1016/j.det.2017.02.002. Epub 2017 Apr 22.
8
ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients.欧洲皮肤病与性病学会/欧洲变态反应与临床免疫学会湿疹工作组2015年关于成人及儿童特应性皮炎诊断与治疗的立场文件。
J Eur Acad Dermatol Venereol. 2016 May;30(5):729-47. doi: 10.1111/jdv.13599. Epub 2016 Mar 23.
9
The role of filaggrin mutations during pregnancy and postpartum: atopic dermatitis and genital skin diseases.丝聚合蛋白突变在妊娠和产后的作用:特应性皮炎和生殖器皮肤病。
Allergy. 2016 May;71(5):724-7. doi: 10.1111/all.12849. Epub 2016 Feb 19.
10
Atopic dermatitis: global epidemiology and risk factors.特应性皮炎:全球流行病学及危险因素
Ann Nutr Metab. 2015;66 Suppl 1:8-16. doi: 10.1159/000370220. Epub 2015 Apr 24.